Table 4

Cytokine profile of peripheral blood CD3+ T cells in patients with spondyloarthropathy at baseline (day 0) and during treatment with anti-TNF-α (infliximab 5 mg/kg intravenously on days 0, 14, and 42)

Day 0 Day 3 Day 7 Day 14 Day 28 Day 42 Day 56 Day 70 Day 84
IFNγ
 % positive cells20.9  (9.9–65.1)23.2  (13.1–70.2)24.94-150  (7.6–69.4)22.6  (4.8–76.7)26.94-150  (10.0–76.1)22.3  (15.5–65.8)26.84-150  (11.1–75.6)22.0  (13.3–52.3)32.74-151 (14.5–78.5)
 MFI110.0 (61.5–192.1)132.6 (89.0–210.2)139.64-150 (90.1–207.2)133.3 (68.0–263.3)134.54-150(86.7–228.8)135.7 (95.1–235.9)136.54-151 (80.4–283.7)153.74-150(67.6–243.5)146.54-151 (85.2–258.9)
IL2
 % positive cells17.5 (7.5–35.4)25.4 (7.2–52.3)32.04-151(13.3–40.6)29.64-151 (4.2–45.0)31.34-151 (11.9–47.2)35.64-151(13.9–43.3)34.74-151 (10.0–56.2)33.54-151 (8.7–56.6)32.64-151(10.1–49.5)
 MFI80.5 (53.4–139.1)84.6 (39.9–129.3)102.2 (58.4–125.8)97.3 (47.2–169.2)95.9 (43.9–168.6)106.64-151 (73.4–183.2)110.34-151(57.1–180.7)112.24-151 (57.0–170.0)125.94-151 (61.9–202.4)
IL4
 % positive cells1.5 (0.3–8.7)1.3 (0.7–2.9)1.0 (0.5–2.8)1.5 (0.7–4.8)1.1 (0.2–2.6)1.8 (0.4–3.9)1.4 (0.4–5.8)0.8 (0.1–2.1)1.0 (0.2–3.7)
 MFI67.6 (31.1–488.7)68.3 (21.6–304.5)66.3 (29.0–242.3)107.5 (29.0–287.7)83.2 (27.3–216.8)42.6 (24.0–80.1)50.9 (24.1–172.2)49.5 (31.0–124.6)51.1 (32.1–159.2)
IL10
 % positive cells3.8 (0.9–15.4)4.2 (0.9–9.3)2.8 (1.6–5.8)3.9 (0.5–6.6)3.0 (1.1–6.6)5.6 (2.3–17.6)4.8 (0.9–16.0)3.2 (1.1–12.6)6.4 (2.2–11.4)
 MFI29.4 (12.8–78.0)31.3 (10.8–80.6)32.4 (6.9–64.8)35.4 (17.5–68.1)38.8 (21.5–105.7)22.2 (16.7–141.9)36.3 (15.1–111.7)43.2 (18.3–135.5)32.6 (16.9–200.2)
  • Results are expressed as median (range).

  • Percentage of positive cells and mean fluorescence intensity (MFI) for interferon (IFN)γ and interleukin (IL)2 were assessed by flow cytometry.

  • 4-150 p⩽0.05,

  • 4-151 p⩽0.01 difference from baseline values.